Tandem Diabetes Care (TNDM) Cash & Current Investments (2013 - 2026)

Tandem Diabetes Care (TNDM) has reported Cash & Current Investments for 14 consecutive years, with $456.0 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash & Current Investments rose 44.59% year-over-year to $456.0 million; the trailing twelve-month figure through Jun 2026 stood at $456.0 million (up 44.59% YoY), and the FY2025 full-year result was $292.7 million, down 33.23% from the prior year.
• Cash & Current Investments retreated to $456.0 million in Q2 2026 per TNDM's latest filing, from $570.3 million in the prior quarter.
• Across five years, Cash & Current Investments topped out at $635.4 million in Q1 2022 and bottomed at $292.7 million in Q4 2025.
• Historically, Cash & Current Investments has averaged $480.2 million across 5 years, with a median of $470.6 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Cash & Current Investments slumped 33.23% in 2025, then soared 54.7% in 2026.
• Over 5 years, Cash & Current Investments stood at $616.9 million in 2022, then dropped by 24.15% to $467.9 million in 2023, then declined by 6.32% to $438.3 million in 2024, then plunged by 33.23% to $292.7 million in 2025, then soared by 55.81% to $456.0 million in 2026.
• According to Business Quant data, Cash & Current Investments over the past three periods registered $456.0 million, $570.3 million, and $292.7 million for Q2 2026, Q1 2026, and Q4 2025 respectively.